1Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumors[J].Eur J Cancer,2006 ;42 ( 8 ) : 1093-103.
2Blanchard DK, Bubbe JM, Metz CE, et al. Tumors of the small intestine [J]. World J Snrg,2000;24(4) :421-42.
8Miettinen M, Sobin LH, Sarlomo-Rikala M, et al. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 ( KIT ) [J]. Mod Pathol,2000 ; 13 ( 10 ) : 1134-42.
9Aparicio T, Boige V, Sabourin JC, et al. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumors[J]. Eur J Surg Oncol, 2004 ;30(10) : 1098-103.
10Davila RE, Faigel DO. GI stromal tumors[J]. Gastrointest Endosc, 2003 ;58( 1 ) :80-8.
5Nilsson B,Bumming P,Meis-Kindblom JM,et al.Gastrointestinal stromal tumors:The incidence,prevalence,clinical course,and prognostication in the preimatinib mesylate era-apopulation-based study in Western Sweden[J].Cancer,2005,103(4):821 -829.
6Bucher P,Egger JF,Gervaz P,et al.An audit of surgical management of gastrointestinal stromal tumours (GIST)[J].Eur J Surg Oncol,2006,32(3):310 -314.
3Mazur M T,Clark H B. Gastric stromal tumors.Reappraisal of histogenesis[J].{H}American Journal of Surgical Pathology,1983,(06):507-519.
4Ma C K,Amin M B,Kintanar E. Immunohistologic characterization of gastrointestinal stromal tumors:a study of 82 cases compared with 11 cases of leiomyomas[J].{H}Modern Pathology,1993,(02):139-144.
5Downs-Kelly E,Rubin B P. Gastrointestinal stromal tumors:molecular mechanisms and targeted therapies[J].Patholog Res Int,2011.708596.
6Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor[J].{H}Human Pathology,2008,(10):1411-1419.
